The Therapeutic Goods Administration says it is moving from education to compliance action after identifying scope creep, inadequate monitoring and a lack of transparency in some AI-powered clinical scribes.
The Therapeutic Goods Administration says it is moving from education to compliance action after identifying scope creep, inadequate monitoring and a lack of transparency in some AI-powered clinical scribes.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.